Sanofi Common Stock Dividends Paid 2010-2024 | SNY
Sanofi annual/quarterly common stock dividends paid history and growth rate from 2010 to 2024. Common stock dividends paid can be defined as the cash outflow for dividends paid on a company's common stock
- Sanofi common stock dividends paid for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
- Sanofi common stock dividends paid for the twelve months ending September 30, 2024 were $-9.986B, a 6.17% increase year-over-year.
- Sanofi annual common stock dividends paid for 2023 were $-4.887B, a 8.69% increase from 2022.
- Sanofi annual common stock dividends paid for 2022 were $-4.496B, a 6.31% decline from 2021.
- Sanofi annual common stock dividends paid for 2021 were $-4.799B, a 5.52% increase from 2020.
Sanofi Annual Common Stock Dividends Paid
(Millions of US $) |
| 2023 |
$-4,887 |
| 2022 |
$-4,496 |
| 2021 |
$-4,799 |
| 2020 |
$-4,547 |
| 2019 |
$-4,310 |
| 2018 |
$-4,472 |
| 2017 |
$-4,210 |
| 2016 |
$-4,183 |
| 2015 |
$-4,115 |
| 2014 |
$-4,900 |
| 2013 |
$-4,848 |
| 2012 |
$-4,497 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$134.124B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
